Cardiology · 1994
4S (Scandinavian Simvastatin Survival Study)
Throughout the late 1980s, cardiologists had a plausible reason to lower cholesterol in patients with coronary disease but no proof that doing so reduced mortality. Trials with earlier lipid-lowering agents, including clofibrate, gemfibrozil, and bile-acid resins, had suggested reductions in coronary events but had not demonstrated a convincing effect on all-cause mortality. Some analyses even suggested possible harm from non-cardiovascular causes. The statins offered more potent LDL reduction than earlier agents, but their effect on hard outcomes remained unproven when the 4S trial began enrolling.
The Scandinavian Simvastatin Survival Study enrolled 4,444 patients across Scandinavian centers, selecting those with established coronary disease and total cholesterol between 5.5 and 8.0 mmol/L. Patients were randomized to simvastatin 20 to 40 mg daily or to placebo and followed for a median of 5.4 years. The trial was run by the Scandinavian investigators as a genuinely industry-independent academic study, with Merck providing simvastatin but the investigators maintaining control of the data.
Simvastatin reduced LDL by roughly 35% from baseline. All-cause mortality fell by 30% in the active treatment group; coronary deaths specifically fell by 42%. The result was consistent across age subgroups and across both men and women. Critically, there was no excess in non-cardiovascular mortality, no signal of cancer, and no worrying pattern of adverse events that might have explained the benefit as an artifact. The proportional reduction in events tracked closely with the degree of LDL lowering.
Terje Pedersen of Aker University Hospital in Oslo was the lead author of the November 1994 Lancet paper. The results were greeted as definitive. Before 4S, physicians could argue that treating cholesterol was theoretically sound; after it, declining to offer a statin to a patient with coronary disease required active justification. The findings moved rapidly into European and American cardiology guidelines.
The following year, WOSCOPS extended statin evidence into primary prevention, showing that pravastatin reduced coronary events in men with elevated cholesterol but no prior heart disease. Together, 4S and WOSCOPS established the statin class as the central pharmacological intervention in cardiovascular risk reduction. Later trials, including CARE and LIPID, confirmed the secondary prevention benefit at lower baseline LDL levels and progressively broadened the treated population.
Key People
- The 4S Investigators — Scandinavian multinational group that designed and ran the trial
- Terje Pedersen — Norwegian cardiologist and lead author of the 1994 Lancet report
- John Kjekshus — Scandinavian cardiologist and key co-investigator in 4S trial design
Lancet. 1994;344(8934):1383-1389.
Related landmarks
- 1994 · Antiplatelet Trialists' Collaboration Overview (Cardiology)
- 1995 · WOSCOPS (West of Scotland Coronary Prevention Study) (Cardiology)
- 1991 · SOLVD Treatment Trial (Cardiology)
- 1988 · ISIS-2 (Second International Study of Infarct Survival) (Cardiology)